A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
B-Cell Receptor IGK Gene Rearrangement, PCR [90363]
MessageFor Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.
Test Code
BCRIGK
Alias/See Also
90363
CPT Codes
81264, 84999 (HCPCS: G0452)
Includes
Test includes pathologist interpretation
Preferred Specimen
5 mL whole blood or 3 mL bone marrow aspirate collected in an EDTA (lavender-top) tube • 8 unstained positively charged slides
Minimum Volume
3 mL whole blood • 1 mL bone marrow aspirate • 4 slides • 1 block
Other Acceptable Specimens
Whole blood or bone marrow aspirate collected in a sodium heparin (green-top) tube • Formalin-fixed, paraffin-embedded tissue • Fresh tissue • Tissues in formalin fixative or RPMI
Instructions
Do not reject specimens, send to laboratory for screening.
8 unstained sections on glass slides labeled with surgical case number (pathology report required, indicate if fixative is not formalin) Please include pathology report for frozen tissue and FFPE cases (partial/preliminary reports acceptable).
Needle washings (acceptable): in alcohol based fixative (eg. CytoLyt) are acceptable.
8 unstained sections on glass slides labeled with surgical case number (pathology report required, indicate if fixative is not formalin) Please include pathology report for frozen tissue and FFPE cases (partial/preliminary reports acceptable).
Needle washings (acceptable): in alcohol based fixative (eg. CytoLyt) are acceptable.
Transport Temperature
Fresh tissue: Frozen
All other specimens: Room temperature
All other specimens: Room temperature
Specimen Stability
Whole blood or bone marrow aspirate
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
FFPE/Slides
Room temperature: 5 years
Refrigerated: 5 yaers
Frozen
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
FFPE/Slides
Room temperature: 5 years
Refrigerated: 5 yaers
Frozen
Methodology
Polymerase Chain Reaction (PCR) • Fragment Analysis
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5 days
Reference Range
See Laboratory Report
Clinical Significance
This assay, which interrogates the immunoglobulin kappa light chain gene (IGK) by a PCR method based on the BIOMED-2 consensus, is useful for establishing clonality of B-cell lymphoid neoplasms and in the identification of minimal residual disease or early recurrence in patients with a previous diagnosis of B-cell neoplasm. It can be used in association with the immunoglobulin heavy chain (IGH PCR assay test code 90362), since false-negative results can occur in up to 10-25% of B-cell malignancies with testing IGK only.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
Last Updated: November 24, 2021